Jerry Colca
Chief Scientific Officer Cirius Therapeutics
Jerry is a widely recognized expert in the pathophysiology of insulin resistance and the pharmacological mechanisms of action of insulin sensitizing drugs. He has dedicated his career to studying the endocrine control of metabolism as it relates to diabetes and has been focused on insulin sensitizers from the early days of their discovery.
Seminars
Thursday 16th April 2026
Redefining the Patient Journey by Leveraging Oral MPC Modulation to Enhance GLP-1 Tolerability and Preserve Lean Mass
3:30 pm
- Utilizing a novel oral Mitochondrial Pyruvate Carrier (MPC) modulator (azemiglitazone) with GLP-1 Receptor Agonists, as evidenced by preclinical and early clinical data showing enhanced metabolic control (improved insulin sensitivity, reduced liver fat) and synergistic efficacy in reducing underlying metabolic dysfunction in Type 2 Diabetes and MASH
- Focusing on the MPC modulator’s potential to preserve or increase lean mass while optimizing fat loss, establishing a path for long-term patient health and adherence that is critical to redefining the patient journey beyond mere weight reduction
- Defining the strategy for next-generation metabolic therapeutics that layer novel oral, non-incretin mechanisms onto incretin backbones to significantly enhance patient comfort and compliance by allowing for lower, better-tolerated doses of the GLP-1 component and establishing a more robust, long-term safety profile
